Multiple U.S. health agencies have released HIV-specific information, and research on HIV and the novel coronavirus is trickling in. Here's what health care providers need to know.
A CROI 2020 roundup of studies on birth control and women living with HIV.
New data shows the drug is not more likely to cause birth defects.
The biggest may be that more of an HIV-positive person’s equally long lifespan will be spent managing comorbidities, one large study found.
Treating newborns with antiretroviral therapy in the hours after birth may help put HIV into remission.
A CROI 2019 study suggests the dynamics of HIV proliferation in the viral reservoir might explain why viral load sometimes fails to become undetectable, especially when adherence is good.
M184V Mutation Associated With Increased Risk of Viral Blip but Not Viral Failure With 3TC-Based Dual Therapy
A retrospective analysis presented at CROI 2018 looked at risk of viral rebound in people who switched to lamivudine (Epivir, 3TC)-based dual antiretroviral therapy.
"Overall, we saw improvements for the whole population, suggesting that the efforts to test [and] diagnose HIV infection sooner, start [antiretroviral] treatment earlier and help patients be retained in care and adherent to their treatment are workin...
Among people starting their first antiretroviral therapy regimen, more advanced HIV disease and black race independently predicted severe weight gain through 96 weeks of follow-up.
Paul Sax, M.D., provides a quick rundown of what he considers the most interesting studies presented at this year's Conference on Retroviruses and Opportunistic Infections.